ICAACReporting at the 32nd Interscience Conference on Anti-microbial Agents and Chemotherapy (ICAAC) held this week inAnaheim, Calif., BioChem Pharma, of Laval, Quebec, said PhaseI/II U.S. and European trials showed positive trends insurrogate markers such as CD4 cells, P24 antigen, B2microglobulin and neopterin. Patients experienced weight gainand increased energy and appetite; no significant drug-relatedtoxicity has been observed.
BioChem expects to begin Phase II/III trials of 3TC in the U.S.and Europe early next year.
Researchers also reported this week at ICAAC that a vaccinedeveloped by The Biocine Co. for herpes simplex Type 2 waswell-tolerated and that subjects developed HSV-specificantibody titers.
Researchers from the University of Washington, Seattle, andBiocine and Chiron Corp., both of Emeryville, Calif., said theyobserved in the early Phase I trials neutralizing antibodiescapable of blocking HSV-2 viral infectivity in tissue culture, aswell as an HSV-specific T cell response. They said patterns andlevels of responses approached those observed among peoplewith natural HSV-2 infection. The studies included peopleinfected with either HSV-1 or HSV-2 and people who show nosigns of exposure to HSV.
Biocine's vaccine consists of recombinant versions of two HSV-2surface antigens, gB2 and gD2, and the company's MF59adjuvant emulsion.
(c) 1997 American Health Consultants. All rights reserved.